中国生物工程杂志

［1］ Sherman P A, Fyfe J A. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc Natl Acad Sci USA,1990, 87 (13) : 51995123. 
［2］ Bushman F D, Craigie R. Activities of human immunodeficiency virus ( HIV ) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc Natl Acad Sci USA, 1991, 88 (4) : 13391343. 
［3］ Chiu T K, Davies D R. Structure and function of HIV1 integrase. Curr Top Med Chem, 2004, 4(9): 965977. 
［4］ Pommier Y, Johnson A A, Marchand C. Integrase inhibitors to treat HIV/Aids. Nat Rev Drug Discov, 2005, 4 ( 3 ) : 236248. 
［5］ Pluymers W, de Clercq E, Debyser Z. HIV1 integration as a target for antiretroviral therapy: a review. Curr Drug Targets Infect Disord, 2001, 1 (2) : 133149. 
［6］ Summa V, Petrocchi A, et al. Discovery of Raltegravir, a potent, selective orally bioavailable HIVintegrase inhibitor for the treatment of HIVAIDS infection. J. Med. Chem. 2008, 51:58435855. 
［7］ Evering T H, Markowitz M. Raltegravir: an integrase inhibitor for HIV1. Expert opinion on investigational drugs. 2008, 17(13):413422. 
［8］ Jenkins T M, Hickman A B, Dyda F, et al. Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues. Proc Natl Acad Sci USA, 1995, 92(13): 60576061. 
［9］ Jenkins T M, Engelman A, Ghirlando R, et al. A soluble active mutant of HIV1 integrase: involvement of both the core and carboxylterminal domains in multimerization. J Biol Chem, 1996,271 (13): 77127718. 
［10］ Lataillade M, Chiarella J, Kozal J M. Natural polymorphism of the HIV1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther, 2007, 12(4): 563570. 
［11］ Jessica Marinello, Christophe Marchand. Comparison of raltegravir and elvitegravir on HIV1 integrase catalytic reactions and on a series of drugresistant integrase mutants. Biochemistry, 2008, 47 (36), 93459354. 
［12］ Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem, 1976, 72: 248254. 
［13］ He H Q, Ma X H, Liu B, et al. A highthroughput format assay for HIV1 integrase strand transfer reaction using magnetic beads. Acta Pharmacol Sin, 2008, 29 (3): 397404. 
［14］ 何红秋,胡建平，刘斌,等．HIV1整合酶核心区野生型和F185K突变型活性和溶解性的比较及分子动力学模拟分析．生物化学与生物物理进展,2009, 36(9): 11461153. He H Q, Hu J P, Liu B, et al.Progress in Biochemistry and Biophysics,2009,36(9):11461153. 
［15］ Carrio M M, Villaverde A. Construction and deconstruction of bacterial inclusion bodies. J Biotechnol, 2002, 96(1): 312. 
［16］ Sotriffer C A, Ni H, Mc Cammon J A. Active site binding modes of HIV1 integrase inhibitors. J Med Chem, 2000, 43:41094117. 
［17］ Lee D J, Robinson W E J. Preliminary mapping of a putativeinhibitorbinding pocket for human immunodeficiency virustype 1 integrase inhibitors. Antimicrob Agents Chemother, 2006, 50:134142. 
［18］ Wilkinson D L, Harrison R G. Predicting the solubility of recombinant proteins in Escherichia coli. Biotechnology (N Y), 1991, 9(5):443448. 
［19］ Bjellqvist B, Hughes G J. The focusing positions of polypeptides in immobilized pH gradients can be predicted from their amino acid sequences. Electrophoresis, 1993, 14: 10231031.